Automated Insulin Pumps Worth the Cost, Study Finds

What Was Studied and Why It Matters

Managing type 1 diabetes (T1D) requires constant attention to blood sugar levels, and the technology used to deliver insulin can make a big difference in both health outcomes and quality of life. Automated insulin delivery (AID) systems — sometimes called "closed-loop" or "artificial pancreas" systems — automatically adjust insulin doses based on real-time continuous glucose monitor (CGM) readings. They are more advanced than standard insulin pumps, but they also cost more.

Researchers in Finland wanted to know: is the extra cost worth it over a lifetime? To find out, they studied 336 people with type 1 diabetes at Kuopio University Hospital and projected their health and financial outcomes over 50 years, comparing AID systems to standard insulin pumps used alongside a CGM.

What the Researchers Found

The results were encouraging for people considering AID technology:

• Better blood sugar control: People using AID systems saw their HbA1c — a key measure of average blood sugar over several months — drop by an average of 12.1 mmol/mol (about 3.3%). Lower HbA1c means fewer dangerous blood sugar swings and a reduced risk of long-term complications.
• More healthy years: AID users gained an average of 2.3 quality-adjusted life-years (QALYs) compared to those using standard pumps with CGM. A QALY measures both how long a person lives and how well they live — so this means more years in better health.
• Fewer complications: The improved blood sugar control translated into delayed or reduced rates of serious diabetes-related complications, such as kidney disease, eye damage, and nerve problems.
• Cost-effective in the long run: While AID systems cost about €26,076 more over a lifetime, the cost per healthy year gained (€11,184 per QALY) fell well below Finland's accepted value threshold of €50,000 per QALY — meaning the technology delivers good value for the investment.

What This Means for Real Patients

If you or your child has type 1 diabetes and you're weighing whether to upgrade to an AID system, this study provides strong evidence that the benefits go beyond convenience. Better blood sugar control today can mean fewer health problems — and better quality of life — decades down the road.

Of course, getting the most from any diabetes technology depends on having the right supplies consistently on hand. Whether you use a CGM, an insulin pump, or an AID system, services like MDS Diabetes can help ensure your monitoring and delivery supplies arrive reliably, so your technology works the way it's supposed to.

Bottom Line

A Finnish study of 336 people with type 1 diabetes found that automated insulin delivery systems significantly improve blood sugar control and overall quality of life compared to standard insulin pumps paired with CGM. Despite costing more upfront, AID systems proved cost-effective over a 50-year horizon — delivering better health outcomes at a price that healthcare systems and families can justify. If you're considering an AID system, talk to your endocrinologist about whether it's right for you.